Trials / Completed
CompletedNCT01711853
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
An Exploratory Study to Investigate the Pharmacokinetics and Effects of DABIgatran Etexilate in Patients With Stable Severe RENAL Disease: DabiRenal
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabigatran Etexilate | Dabigatran Etexilate 75mg twice daily |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2012-10-22
- Last updated
- 2015-01-13
- Results posted
- 2015-01-13
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01711853. Inclusion in this directory is not an endorsement.